Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 4/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | RAB9A | P51151 | 5/20 | 0.77 |
| ▸ | PKM | P14618 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CASP1 | P29466 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755109 | 1.00 | ESRRG (1.00) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL25424222 | 0.89 | MAPT (0.82) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL18127345 | 0.89 | HDAC6 (1.00) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL25424218 | 0.89 | MAPT (0.82) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL19283311 | 0.88 | ESRRG (0.79) | ESRRGHDAC6MAPTKDM4EALDH1A1 | |
| SCHEMBL19283313 | 0.88 | ESRRG (0.79) | ESRRGHDAC6MAPTKDM4EALDH1A1 | |
| SCHEMBL6634490 | 0.87 | MAPT (1.00) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL21531471 | 0.87 | MAPT (0.89) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL20328281 | 0.87 | MAPT (0.89) | ESRRGHDAC6HDAC8MAPTKDM4E | |
| SCHEMBL1563651 | 0.87 | MAPT (1.00) | ESRRGHDAC6HDAC8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | CHOUDHARY MUHAMMAD IQBAL (PK) | 2017-08-31 | — | — | US | disclosed |
| US-20130274233-A1 | MODULATORS OF HEDGEHOG SIGNALING PATHWAY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-10-17 | — | — | US | disclosed |
| US-20130274233-A1 | MODULATORS OF HEDGEHOG SIGNALING PATHWAY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274233-A1 | MODULATORS OF HEDGEHOG SIGNALING PATHWAY | GLI1, SMO, SHH | ESRRG 545/4885HDAC6 11/4885HDAC8 379/4885 |
| US-20170246130-A1 | 4-HYDROXYBENZOHYDARZIDE-A NEW CLASS OF ANGIOGENIC ENZYME THYMIDINE PHOSPHORYLASE INHIBITORS | TYMP, DPYD, FLT4 | ESRRG 4221/4885HDAC6 1811/4885HDAC8 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.